What is the starting dose of rosuvastatin (Crestor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose of Rosuvastatin

The standard starting dose of rosuvastatin is 10 mg once daily for most adult patients, though 5 mg once daily is recommended for Asian patients, those with severe renal impairment, and patients on certain interacting medications. 1

Standard Dosing for General Population

  • The FDA-approved dosage range for rosuvastatin is 5-40 mg orally once daily, with the specific dose depending on the patient's indication, baseline LDL-C level, and cardiovascular risk 1

  • For most adult patients without special considerations, initiate rosuvastatin at 10 mg once daily 1

  • The medication can be taken at any time of day, with or without food 1

Special Population Dosing Adjustments

Asian Patients

  • Start at 5 mg once daily in Asian patients due to significantly increased rosuvastatin plasma concentrations (approximately 2-fold higher than in Caucasian patients) 2, 1

  • Exercise caution when considering doses above 20 mg daily in this population 1

Renal Impairment

  • For severe renal impairment (CrCl <30 mL/min/1.73 m²) not on hemodialysis: start at 5 mg once daily and do not exceed 10 mg daily 3, 1

  • No dose adjustment needed for mild to moderate renal impairment 3, 1

Pediatric Patients

  • Ages 8-10 years with heterozygous familial hypercholesterolemia (HeFH): 5-10 mg once daily 1

  • Ages ≥10 years with HeFH: 5-20 mg once daily 1

  • Ages ≥7 years with homozygous familial hypercholesterolemia (HoFH): 20 mg once daily 1

Drug Interaction-Based Dose Modifications

Severe Restrictions (Maximum 5 mg daily)

  • Cyclosporine: Do not exceed 5 mg once daily due to 7-fold increase in rosuvastatin exposure 2, 1

  • Darolutamide: Do not exceed 5 mg once daily 1

Moderate Restrictions (Maximum 10 mg daily)

  • Teriflunomide, enasidenib, capmatinib: Do not exceed 10 mg once daily 1

  • Gemfibrozil: Avoid concomitant use if possible; if necessary, start at 5 mg and do not exceed 10 mg daily 1

  • Protease inhibitors (atazanavir/ritonavir, lopinavir/ritonavir): Start at 5 mg and do not exceed 10 mg daily 1

Less Restrictive Modifications (Maximum 20 mg daily)

  • Fostamatinib, febuxostat, tafamidis: Do not exceed 20 mg once daily 1

Intensity-Based Dosing Strategy

Moderate-Intensity Therapy (30-49% LDL-C reduction)

  • Rosuvastatin 5-10 mg daily achieves moderate-intensity statin therapy 4, 3

  • Appropriate for primary prevention in patients aged 40-75 years without established ASCVD 3

High-Intensity Therapy (≥50% LDL-C reduction)

  • Rosuvastatin 20-40 mg daily achieves high-intensity statin therapy 4, 3

  • Recommended for secondary prevention in patients with established ASCVD 3

Common Pitfalls to Avoid

  • Failing to reduce the starting dose in Asian patients can lead to increased risk of myopathy due to higher drug exposure 2, 1

  • Not adjusting for severe renal impairment increases the risk of adverse effects 1

  • Overlooking drug interactions with immunosuppressants (particularly cyclosporine) can result in dangerous elevations in statin levels and muscle toxicity 2, 1

  • Starting at unnecessarily high doses when 5-10 mg may be sufficient for many patients to reach LDL-C goals 5, 6

Monitoring and Titration

  • Assess LDL-C levels 4-12 weeks after initiation and adjust dose as needed to achieve target goals 3, 1

  • If a dose is missed, do not double up; simply resume with the next scheduled dose 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Rosuvastatin Dosage and Administration Guidelines for Hyperlipidemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Statin Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Review of efficacy of rosuvastatin 5 mg.

International journal of clinical practice, 2005

Research

Efficacy and safety of rosuvastatin in treatment of dyslipidemia.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.